DAIICHI SANKYO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: CS-1008 (humanized anti-DR5 antibody)Drug: gemcitabine
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT00521404
- Locations
- 🇺🇸
Georgia Cancer Specialists, Tucker, Georgia, United States
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
Phase 2
Completed
- Conditions
- Atrial FibrillationThromboembolism
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1146
- Registration Number
- NCT00504556
Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
Phase 3
Completed
- Conditions
- Type 2 DiabetesHyperlipidemia
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 169
- Registration Number
- NCT00484419
Study of Rivoglitazone in Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1912
- Registration Number
- NCT00484198
A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Phase 1
Completed
- Conditions
- AMLMDSAcute Myeloid LeukemiaMyelodysplastic SyndromeLeukemia
- Interventions
- Drug: AC220
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 76
- Registration Number
- NCT00462761
- Locations
- 🇬🇪
Hematology and Chemotherapy Clinic, T'bilisi, Georgia
🇬🇪Chemotherapy and Immunotherapy Clinic, T'Bilisi, Georgia
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 278
- Registration Number
- NCT00430638
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 972
- Registration Number
- NCT00430508
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Phase 3
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1011
- Registration Number
- NCT00430950
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2009-09-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 178
- Registration Number
- NCT00412932
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
Phase 1
Completed
- Conditions
- Neoplasm
- Interventions
- Drug: CS-7017
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT00408434
© Copyright 2025. All Rights Reserved by MedPath